Navigation Links
XTENT Announces 2007 Financial Results Conference Call
Date:2/12/2008

MENLO PARK, Calif., Feb. 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm or by calling 877-627-6580 (domestic), 719-325-4903 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.

An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
2. XTENT Announces Third Quarter 2007 Financial Results
3. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
4. USHEALTH Group Announces Appointment of Executive Vice President
5. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
6. Herley Industries Announces the Passing of Its Former President
7. GPhA Announces 2008-2009 Executive Committee; Teva North Americas Bill Marth Elected as Chairman of the Board
8. Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil
9. Methodist Healthcare - Memphis Hospitals Announces the Commencement of the Tender Offer for Certain Designated Maturities of:
10. Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis Pathogen Identification Technology
11. Sosei Announces Start of AD 923 Phase III Studies in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: